Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio's Electroporation DNA Delivery Technology
Inovio Biomedical Corp., focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced that interim data from a clinical study of an experimental DNA-based prostate cancer vaccine demonstrated that Inovio's DNA delivery technology significantly enhanced the potency of the gene-based vaccine.
The results demonstrated safety, tolerability and significantly higher antibody responses for patients who received the vaccine with Inovios delivery system versus those who were treated without it. Inovios electroporation-mediated DNA delivery system is designed to enhance the potency of DNA-based immunotherapies against cancers and infectious diseases.
An analysis of interim data from the first and partially from the second dose treatment groups demonstrated the following points:
1. Electroporation appears safe and it is well tolerated.
2. The number of patients with significant antibody responses was four of 10 in the patient groups treated without electroporation compared to nine of 10 in the patient groups treated with electroporation.
3. The magnitude of the antibody response was significantly higher in patients treated using electroporation. Data on the T-cell response is being compiled.
The investigators continue to enroll and treat patients in the higher-dosage treatment groups.
Other news from the department research and development
